- |||||||||| lamivudine HBV / Generic mfg.
HEPATITIS B VIRUS REACTIVATION IN CANCER PATIENTS RECEIVING CHEMOTHERAPY (Hall A, Poster Hall - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_1859; Chronic hepatitis B patients with TC and CC genotype in rs3826160 have high telbivudine plasma concentration are at risk of elevated creatine kinase. Among the 31 studies, the pooled HBV reactivation rates for patients who received prophylactic Tenofovir Disoproxil Fumarate (TDF) were 1% (95% CI: 0%
- |||||||||| Tyzeka (telbivudine) / Novartis
Review, Journal: Telbivudine-induced rhabdomyolysis in a patient undergoing haemodialysis: A case report and review of literature. (Pubmed Central) - Dec 27, 2023 While his CK and myoglobin levels decreased rapidly, his muscle weakness and pain improved slowly. Learning points include: patients undergoing haemodialysis and concomitantly receiving antiviral treatment for HBV, should have their serum levels of CK and myoglobin monitored regularly; treatment with corticosteroids maybe required; relief from rhabdomyolysis-induced muscle weakness and pain may be slow due to nerve fibre damage.
- |||||||||| ebselen (SPI-1005) / Sound Pharma, Cu(II)ATSM / Collaborative Medicinal Development, Tyzeka (telbivudine) / Novartis
A polytherapy approach demonstrates therapeutic efficacy in familial SOD1 ALS models (Event Halle, Messe Basel, Ground Floor) - Nov 7, 2023 - Abstract #ALSMND2023ALS_MND_476; Furthermore, multiple different ratios of the CET treatment) were found to significantly improve survival compared to the highest concentration of CuATSM alone tested (0.5 mM) (p < 0.05), despite using less than half the concentration of CuATSM. In addition, CET treatment significantly reduced the percentage of cells containing inclusions compared to the highest concentration of CuATSM alone.
- |||||||||| Tyzeka (telbivudine) / Novartis
Journal, IO biomarker: IL-21 collaborates with anti-TIGIT to restore NK cell function in chronic HBV infection. (Pubmed Central) - Nov 3, 2023 production in splenic NK cells rather than intrahepatic NK cells, indicating a brand-new mechanism of IL-21 in HBV clearance when combined with anti-TIGIT. Overall, our findings contribute to the design of immunotherapy through enhancing the antiviral efficacy of NK cells in chronic HBV infection.
- |||||||||| lamivudine HBV / Generic mfg.
Journal: High Frequency of Antiviral Resistance Mutations in HBV Genotypes A2 and H: Multidrug Resistance Strains in Mexico. (Pubmed Central) - Aug 14, 2023 Lamivudine (3TC), telbivudine (LdT), entecavir (ETV), adefovir (ADF), and tenofovir (TFV) are drugs used to treat hepatitis B virus (HBV) infection, but specific mutations allow some viruses to become resistant to antiviral drugs or to acquire immune escape capacities...Resistance mutations were found in genotypes A2 (11.8%, 2/17), and H (10.2%, 11/108), and escape mutations were detected in HBV genotypes A2 (11.8%, 2/17), H (10.2%, 11/108), F1b (9.1%, 1/11) and G (5.6%, 1/18). The highest prevalence of antiviral resistance mutations or escape mutations was detected in HBV genotypes A2 and H. The earliest cases of HBV multidrug resistance were detected in Mexico.
- |||||||||| Vemlidy (tenofovir alafenamide) / Gilead, Tyzeka (telbivudine) / Novartis
Break Down of a Root Cause: A Case of Potential Tenofovir Induced Rhabdomyolysis (Exhibit Hall) - Jul 29, 2023 - Abstract #ACG2023ACG_2937; Our patient presented with RM without common risk factors and an unrevealing workup...In a case of chronic hepatitis B with a patient on telbivudine, RM occurred shortly after the addition of tenofovir, leading to suspicion for a combination effect...To the best of our knowledge, there has not been a case of RM in a non-HIV patient with chronic hepatitis B on tenofovir alone. While our case cannot prove causation, we suggest a high level of suspicion should be given to tenofovir toxicity in future cases of RM if no other obvious etiology is identified.
- |||||||||| Cytovene (ganciclovir) / Roche, Arbidol (umifenovir) / Pharmstandard, Tyzeka (telbivudine) / Novartis
Biomarker, Journal: Stability and WBE biomarkers possibility of 17 antiviral drugs in sewage and gravity sewers. (Pubmed Central) - May 17, 2023 As for the other 8 unstable drugs (abacavir, arbidol, ribavirin, zidovudine, ritonavir, lopinavir, remdesivir and efavirenz), their attenuation was driven by adsorption, biodegradation and diffusion...Compared with current classification method, this framework considered the influences of residence time and different removal mechanisms, which additionally screened four antiviral drugs as viable WBE biomarkers. This is the first study to report the stability of antiviral drugs in gravity sewers.
- |||||||||| Vemlidy (tenofovir alafenamide) / Gilead, Tyzeka (telbivudine) / Novartis
Hepatitis delta treatment utilization in the United States: an analysis of commercially insured adults with hepatitis delta virus infection (Poster Area) - Apr 12, 2023 - Abstract #EASLILC2023EASL_ILC_330; In a large US national, primarily commercial, healthcare claims database, fewer than 40% of patients with HDV were treated with HBV-specific antiviral therapies, and very few patients (1.1%) were treated with Peg-IFN, the current off label standard of care for HDV infection. Greater awareness of the importance of timely initiation of antiviral therapy for patients with combined HBV/HDV infection is urgently needed.
- |||||||||| lamivudine HBV / Generic mfg.
Journal: Long-term follow-up of treatment-na (Pubmed Central) - Apr 4, 2023 However, drug resistance and virological breakthrough in the LAM group and side effects in the LdT group were detected during the long-term follow-up. Moreover, HBsAg seroclearance was achieved at very low rates with oral antiviral agents.
- |||||||||| lamivudine HBV / Generic mfg.
Optimal Management of Pregnant Women With HBV Infection and Other Liver Diseases (3F Plenary Hall) - Dec 18, 2022 - Abstract #APASL2023APASL_206; Tenofovir Disoproxil Fumarate should be the drug of choice during pregnancy in view of its potent effect, and the possibility of pre-existing or emergent resistant mutants from prior lamivudine and telbivudine treatment...Acute flare of chronic HBV infection could occur during pregnancy and after delivery which could also lead to major maternal morbidity and mortality. Other liver diseases complicating pregnancy will also be discussed.
- |||||||||| lamivudine HBV / Generic mfg.
Retrospective data, Journal: Meta-Analysis of the Risk for Abnormal Liver Function in Pregnancy with High HBV DNA After Antiviral Therapy Withdrawal. (Pubmed Central) - Sep 20, 2022 The telbivudine treatment group was compared with the control group: at 0-12 weeks: RR = 0.77; 95% CI, 0.43-1.39; at 12-24 weeks: RR = 0.62, 95% CI, 0.23-1.64...There was no significant difference between the 4-week group and the 4-12 week group and the control group. In pregnant women with a high HBV DNA load, immediate withdrawal after antiviral treatment in the second or third trimester of pregnancy did not increase the risk for ALF after delivery.
- |||||||||| Tyzeka (telbivudine) / Novartis
Journal: Infant immune response to hepatitis B vaccine after fetal exposure to telbivudine. (Pubmed Central) - Apr 12, 2022 Children in the LdT and control group had comparable levels of interleukin-2, interleukin-4, interleukin-6, interleukin-10, interleukin-12, interferon-α, interferon-γ and tumor necrosis factor-α (P > .05). Intrauterine exposure to LdT was safe to infant immune response to HepB after birth.
- |||||||||| Tyzeka (telbivudine) / Novartis
Clinical, Journal: Developmental consequences of children born from mothers with telbivudine treatment during late pregnancy: A prospective study with 3-year follow-up. (Pubmed Central) - Jan 27, 2022 Multivariate regression analyses showed that exposure to LdT during pregnancy was independently associated with infant's development in gross motor (OR 6.49, 95% CI 1.37-30.20, P = 0.02) and adaptive (OR 0.18, 95% CI 0.05-0.71, P = 0.01) at 36 months. These results suggest that prenatal LdT exposure might affect neurological development in long-term observation.Abbreviations: LdT: telbivudine; HBV: hepatitis B virus; HBsAg: hepatitis B surface antigen; HBeAg: hepatitis Be antigen; HbsAb: hepatitis B surface antibody; ALT: alanine aminotransferase; NA: nucleoside/nucleotide analog; LAM: lamivudine; MTCT: mother-to-child transmission; GDS: Gesell Developmental Schedule; OR: odds ratio; CI: confidence interval; DQ: developmental quotient; RMB: renminbi; BMI: body mass Index; HBIG: hepatitis B immunoglobulin.
- |||||||||| entecavir / Generic mfg., adefovir dipivoxil / Generic mfg.
Clinical, Journal, Adverse events, Real-world evidence: Adverse Events During Pregnancy Associated With Entecavir and Adefovir: New Insights From a Real-World Analysis of Cases Reported to FDA Adverse Event Reporting System. (Pubmed Central) - Jan 21, 2022 We found a moderate or strong signal for increased risk of spontaneous abortion when comparing ETV with tenofovir disoproxil fumarate (TDF) and telbivudine (LdT), with RORs equal to 1.58 (95% CI, 1.09-2.30) and 2.13 (95% CI, 1.04-4.36), respectively...Futhermore, a strong signal for increased risk of spontaneous abortion was identified in patients with HBV infection when comparing ETV or ADV with lamivudine (LAM), with RORs of 3.55 (95% CI, 1.54-8.18) and 2.85 (95% CI, 1.15-7.08), respectively...Moreover, no obvious signal association of human teratogenicity with exposure to ETV or ADV was identified in fetuses during pregnancy. Nevertheless, owing to the limitations of a spontaneous reporting database, which inevitably contains potential biases, there is a pressing need for well-designed comparative safety studies to validate these results in clinical practice.
|